The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| BIOHAVEN PHARMACTL HLDG CO L | COM | G11196105 | 161,900 | 1,111,111 | SH | DFND | 1 | 1,111,111 | 0 | 0 | |
| VIRACTA THERAPEUTICS INC | COM | 92765F108 | 18 | 3,700 | SH | DFND | 1 | 3,700 | 0 | 0 | |
| EPIZYME INC | COM | 29428V104 | 46,807 | 31,841,394 | SH | DFND | 1 | 31,841,394 | 0 | 0 | |
| EPIZYME INC | COM | 29428V904 | 3,786 | 2,575,450 | SH | Call | DFND | 1 | 2,575,450 | 0 | 0 |
| BIOCRYST PHARMACEUTICALS INC | COM | 09058V103 | 40,692 | 3,846,154 | SH | DFND | 1 | 3,846,154 | 0 | 0 | |